预约演示
更新于：2026-02-26
Tafluprost/Timolol Maleate
他氟前列腺素/马来酸噻吗洛尔
更新于：2026-02-26
概要
基本信息
药物类型 小分子化药 |
别名 Tafluprost/timolol、Tapcom-S、Taptiqom + [12] |
作用方式 激动剂、拮抗剂 |
作用机制 PTGFR激动剂(前列腺素FP受体激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H28N4O7S |
InChIKeyWLRMANUAADYWEA-NWASOUNVSA-N |
CAS号26921-17-5 |
查看全部结构式(2)
关联
20
项与 他氟前列腺素/马来酸噻吗洛尔 相关的临床试验KCT0010003
A prospective multi-centre clinical trial to evaluate the safety and the efficacy in Primary open-angle glaucoma or ocular hypertension patients switching from preserved latanoprost monotherapy to preservative-free tafluprost/timolol fixed-combination therapy. (TATI-Study)
NCT04828057
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
NCT04489810
GlutDigest - Enzymes-assisted Gluten Digestion
100 项与 他氟前列腺素/马来酸噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 他氟前列腺素/马来酸噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 他氟前列腺素/马来酸噻吗洛尔 相关的专利（医药）
登录后查看更多信息
11
项与 他氟前列腺素/马来酸噻吗洛尔 相关的文献（医药）2024-12-03Beneficial Microbes
Bacillus subtilis DE111 partially reverses endothelial dysfunction in western-diet fed mice
Article
作者: Y. Wei ; C.L. Gentile ; B.D. Risk ; G.C. Stark ; M. Zhang ; G.D. Brown ; T.L. Weir ; E.L. Graham
Abstract:
Imbalances in the gut microbiome have emerged as an important factor in endothelial dysfunction, a significant risk factor for cardiovascular disease. Thus, interventions targeting the microbiome may prove helpful in preventing or reversing this impairment. We previously reported that spore-forming Bacillus subtilis DE111 improved endothelial function in a cohort of healthy, non-obese humans after a four-week intervention. Building on these promising results, the present study sought to investigate whether administering B. subtilis DE111 could reverse endothelial dysfunction in mice with diet-induced obesity. Male C57BL/6J mice were fed a Western diet (WD; n = 24) or standard diet (SD; n = 24) for ten weeks to induce endothelial dysfunction, after which half of the animals in each group (n = 12) were allocated to receive B. subtilis DE111 (hereafter, PB) formulated into the diet for an additional eight weeks. Outcomes included endothelial-dependent arterial dilation, glucose tolerance, body weight changes, microbiota profiles, and assessments of intestinal permeability and mucosal immunity markers. Furthermore, a cell culture model of gut barrier function was used to assess the effects of PB on gut barrier integrity. PB treatment significantly attenuated WD-induced mesenteric endothelial-dependent arterial dilation, independent of changes in other cardiometabolic parameters or changes in gut barrier function. In vitro trans-epithelial electrical resistance of the Caco-2 cell culture confirmed that neither PB-conditioned media nor faecal waters from B. subtilis-treated human stool resulted in gut barrier improvements, nor did they protect against inflammation-associated barrier disruptions. Unsurprisingly, microbiota analysis revealed significant differences in Shannon’s alpha diversity of WD-fed animals compared to SD. These data suggest that PB consumption significantly attenuated WD diet-induced endothelial dysfunction; however, the underlying mechanisms of this protection were not determined. Improvement in endothelial function was independent of PB-mediated changes to body weight or gut barrier function. Further studies should explore B. subtilis-mediated immune responses or metabolite production as mechanisms underlying these endothelial protective effects.
2023-02-23Beneficial microbes
Acute physiological effects following Bacillus subtilis DE111 oral ingestion – a randomised, double blinded, placebo-controlled study
Article
作者: C. Phipps ; A. Brodkorb ; E. Khokhlova ; S. Mazhar ; J. Deaton ; K. Rea ; M. Buckley ; J. Colom ; A. Simon ; D. Freitas
Previous studies using ileostomy samples from study participants demonstrated that the spore-forming probiotic Bacillus subtilis DE111® can germinate in the small intestine as early as 4 hours after ingestion. Metabolomics, proteomics and sequencing technologies, enabled further analysis of these samples for the presence of hypoglycaemic, hypolipidemic, antioxidant, anti-inflammatory and antihypertensive molecules. In the DE111 treatment group, the polyphenols trigonelline and 2,5-dihydroxybenzoic acid, orotic acid, the non-essential amino acid cystine and the lipokine 12,13-diHome were increased. DE111 also reduced acetylcholine levels in the ileostomy samples, and increased the expression of leucocyte recruiting proteins, antimicrobial peptides and intestinal alkaline phosphatases of the brush border in the small intestine. The combination of B. subtilis DE111 and the diet administered during the study increased the expression of the proteins phosphodiesterase ENPP7, ceramidase ASAH2 and the adipokine Zn-alpha-2-glycoprotein that are involved in fatty acid and lipid metabolism. Acute B. subtilis DE111 ingestion had limited detectable effect on the microbiome, with the main change being its increased presence. These findings support previous data suggesting a beneficial role of DE111 in digestion, metabolism, and immune health that appears to begin within hours of consumption.
2022-05-01FASEB JOURNAL
RETRACTED:
Bacillus Subtilis
DE111 Improves Endothelial Dependent Vascular Dilation in Mice Fed a Western Diet
Article
作者: Risk, Briana D.
Vascular dysfunction often precedes the development of cardiovascular disease in which data from our lab and others suggest a role of the gut microbiome in the development of this defect. In a pilot study of healthy humans, we observed that the spore‐based probiotic, Bacillus Subtilis DE111(DE111), improved reactive hyperemia index (RHI) scores, indicating improved vascular dilation. To further explore whether DE111 impacts cardiovascular function, the current study examined its efficacy in a diet‐induced obesity model in mice. Male C57/BJ mice were fed a standard diet (SD; n=24) or Western diet (WD; n=24) for 8 weeks to induce vascular dysfunction and were then further divided such that (n=12) half of the animals on each diet received 1billion colony forming units per day (CFU/d) of DE111. Weekly body weight was measured until termination at 6 months of age. WD and WD+DE111 mice exhibited similar increases in body weight (SD: 31.2±2.3 vs WD: 47.4±3.3 and WD+DE111: 45.7±4.0) and impairments in glucose tolerance compared to SD mice (SD: 237.1±68.0 vs WD: 410±26.9 and WD+DE111: 460±116.8, p<0.05). A 28% decrease in vessel dilation was observed with mice on a WD as compared to mice on a SD after addition of the endothelial‐dependent dilator acetylcholine (AUC, 918.3±49.25, p<0.05). However, the addition of DE111 improved endothelial mediated vessel dilation in mice fed a WD+DE111 (AUC, 991.7±47.9, p<0.05). This increase was observed independent of body weight changes and improvement in glucose tolerance. In conclusion, the addition of DE111 increased endothelial‐dependent dilation in mice fed a WD. Further analyses are underway to establish the mechanisms of this gut‐vasculature crosstalk, but our animal and human studies both suggest that the novel probiotic, DE111 may support cardiovascular health.
27
项与 他氟前列腺素/马来酸噻吗洛尔 相关的新闻（医药）2026-01-20
2025-10-23
一致性评价
2025-10-22
抗体药物偶联物
100 项与 他氟前列腺素/马来酸噻吗洛尔 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 开角型青光眼 | 中国 | 2025-03-25 | |
| 青光眼 | 日本 | 2013-09-20 | |
| 高眼压症 | 日本 | 2013-09-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 42 | Preserved latanoprost | 觸鬱製壓鏇鏇鹹膚遞鹽(醖壓醖餘艱醖蓋糧壓築) = Hyperemia was more common with preserved latanoprost (21.4 vs. 7.1%; P = 0.031) 鹹觸觸糧願鬱鹽襯獵繭 (襯窪衊憲襯範壓淵餘築 ) | - | 2018-12-01 | ||
N/A | 1,157 | 窪膚糧鏇製窪願鬱壓夢(糧積艱齋襯觸糧壓網築) = few adverse events 獵夢壓範醖獵窪遞鹽鏇 (餘壓願廠積淵壓壓鬱衊 ) | 积极 | 2016-10-16 | |||
临床3期 | 166 | Placebo+DE-111 (DE-111) | 範糧襯襯艱願製廠鑰糧(觸膚觸選餘廠憲蓋夢網) = 遞簾範積淵窪鑰鏇觸築 選衊襯艱簾鹹繭鬱構衊 (蓋艱積艱觸糧糧顧顧築, 2.1) 更多 | - | 2015-05-15 | ||
Timolol (Timolol) | 範糧襯襯艱願製廠鑰糧(觸膚觸選餘廠憲蓋夢網) = 壓願壓鑰選範醖鏇構觸 選衊襯艱簾鹹繭鬱構衊 (蓋艱積艱觸糧糧顧顧築, 2.1) 更多 | ||||||
临床3期 | 489 | Placebo+DE-111 (DE-111) | 糧壓觸選憲鏇衊壓願遞(壓齋鹹選鏇夢夢廠築艱) = 簾獵選選糧顧鏇窪艱鹽 觸構夢鬱鬱醖衊構膚顧 (築蓋簾衊構鏇鹹顧獵糧, 1.8) 更多 | - | 2015-05-14 | ||
(Tafluprost) | 糧壓觸選憲鏇衊壓願遞(壓齋鹹選鏇夢夢廠築艱) = 淵鏇鹽鹹醖齋觸鏇繭醖 觸構夢鬱鬱醖衊構膚顧 (築蓋簾衊構鏇鹹顧獵糧, 1.7) 更多 | ||||||
临床3期 | 148 | Timolol+Tafluprost+DE-111 | 鬱鏇壓鏇廠醖網顧鹽鏇(衊齋製構獵網範淵淵齋) = 繭積廠鹽蓋觸網鬱壓製 壓醖鏇窪簾鬱憲鹽蓋淵 (積鬱網願衊醖觸簾憲繭, 2.2) 更多 | - | 2015-05-14 | ||
临床3期 | - | Preservative-free FDC tafluprost-timolol | 夢構簾範獵範鏇廠夢艱(衊遞艱鏇憲蓋願醖蓋鏇) = 齋繭鑰鹽鹹獵顧壓遞壓 衊鏇衊蓋遞鬱構遞夢積 (遞鹽蓋鏇積艱遞蓋蓋簾 ) 更多 | 积极 | 2013-06-01 | ||
Preservative-free NFC tafluprost-timolol | 夢構簾範獵範鏇廠夢艱(衊遞艱鏇憲蓋願醖蓋鏇) = 積築構鹹糧顧鑰壓繭鑰 衊鏇衊蓋遞鬱構遞夢積 (遞鹽蓋鏇積艱遞蓋蓋簾 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用